التفاصيل البيبلوغرافية
| العنوان: |
Renal function after liver transplantation : Real-world experience with basiliximab induction and delayed reduced-dose tacrolimus |
| المؤلفون: |
Cederborg, Anna, Noren, Asa, Barten, Thijs, Lindkvist, Bjorn, Bennet, William, Herlenius, Gustaf, Castedal, Maria, Marschall, Hanns-Ulrich, Åberg, Fredrik |
| المساهمون: |
Clinicum, HUS Abdominal Center, IV kirurgian klinikka |
| بيانات النشر: |
EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC |
| سنة النشر: |
2022 |
| المجموعة: |
Helsingfors Universitet: HELDA – Helsingin yliopiston digitaalinen arkisto |
| مصطلحات موضوعية: |
Clinical research, Hepatology, Immunosuppression, Kidney injury, GLOMERULAR-FILTRATION-RATE, CHRONIC KIDNEY-DISEASE, DACLIZUMAB ZENAPAX, RECIPIENTS, GFR, DYSFUNCTION, INJURY, General medicine, internal medicine and other clinical medicine, Surgery, anesthesiology, intensive care, radiology |
| الوصف: |
Background: Routine use of delayed reduced-dose calcineurin-inhibitor treatment with induction immunosuppression in liver transplantation to minimize post-operative kidney injury is still scarce. im: To evaluate real-world experience of basiliximab induction with delayed reduced-dose tacrolimus. Methods: In a retrospective cohort study, kidney function was evaluated pre-and postoperatively by mea-sured glomerular filtration rate (mGFR). Adult patients undergoing liver transplantation between 20 0 0 and 2017 were divided into a conventional treatment group (immediate-introduction of tacrolimus, tar-get trough levels 10-15 ng/mL, and corticosteroids, n = 203) and a revised treatment group (basiliximab induction, reduced-dose tacrolimus, target through levels 5-8 ng/mL, delayed until day three, and my-cophenolate mofetil 20 0 0 mg/day, n = 343). Results: Mean mGFR was similar between groups at wait-listing (85.3 vs 84.1 ml/min/1.73m2, p = 0.60), but higher in the revised treatment group at 3 (56.8 vs 63.4 ml/min/1.73m2, p = 0.004) and 12 months post-transplant (60.9 vs 69.7 ml/min/1.73m2, p < 0.001); this difference remained after correcting for mul-tiple confounders and was independent of pre-transplant mGFR. In the revised treatment group, biopsy proven acute rejection rate was lower (38% vs. 21%, p < 0.001), and graft-survival better ( p = 0.01). Conclusion: Basiliximab induction with delayed reduced-dose tacrolimus is associated with less kidney injury when compared to standard-dose tacrolimus, without increased risk of rejection, graft loss or death. (c) 2021 The Authors. Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l. ; Peer reviewed |
| نوع الوثيقة: |
article in journal/newspaper |
| وصف الملف: |
application/pdf |
| اللغة: |
English |
| Relation: |
Grants from the Swedish state under the agreement between the Swedish government and the county councils, ALF-agreement (ALFGBG-717231) to HUM.; Cederborg , A , Noren , A , Barten , T , Lindkvist , B , Bennet , W , Herlenius , G , Castedal , M , Marschall , H-U & Åberg , F 2022 , ' Renal function after liver transplantation : Real-world experience with basiliximab induction and delayed reduced-dose tacrolimus ' , Digestive and Liver Disease , vol. 54 , no. 8 , pp. 1076-1083 . https://doi.org/10.1016/j.dld.2021.12.006; http://hdl.handle.net/10138/347571; 5916a1ca-4a42-4a76-8cdd-2d2c347f1225; 000837291300011 |
| الاتاحة: |
http://hdl.handle.net/10138/347571 |
| Rights: |
cc_by ; info:eu-repo/semantics/openAccess ; openAccess |
| رقم الانضمام: |
edsbas.BAA625C0 |
| قاعدة البيانات: |
BASE |